与年龄相关性黄斑变性相关的3型黄斑新生血管中色素上皮脱离和视网膜下液的发生率及发生时间
这项回顾性研究纳入84例初诊时无视网膜下液的初治3型黄斑新生血管患者,均先接受三次负荷注射雷珠单抗或阿柏西普后按需治疗。初诊无浆液性色素上皮脱离的32例中20例(62.5%)平均10.9个月后发生色素上皮脱离;初诊有浆液性色素上皮脱离而无视网膜下液的52例中15例(28.8%)平均11.2个月后发生视网膜下液。作者认为这些病变多在诊断后12个月内出现,提示早期治疗期需积极治疗以改善疗效。
要点
- 初诊无浆液性色素上皮脱离的32例中20例(62.5%)发生色素上皮脱离,平均10.9±5.1个月。
- 初诊有浆液性色素上皮脱离而无视网膜下液的52例中15例(28.8%)发生视网膜下液,平均11.2±6.4个月。
- 色素上皮脱离和视网膜下液多在诊断后12个月内出现,作者提示早期治疗期需积极治疗。
核心结论
- 色素上皮脱离和视网膜下液在相当比例的3型黄斑新生血管患者中发生,平均发生时间在诊断后12个月内,作者提示早期治疗期需积极治疗以改善疗效。
研究设计与样本
- 回顾性研究纳入84例初诊时无视网膜下液的初治3型黄斑新生血管患者,均先接受三次负荷注射雷珠单抗或阿柏西普,之后按需治疗。
主要发现
- 平均随访41.3±20.7个月;初诊无浆液性色素上皮脱离的32例中20例(62.5%)发生色素上皮脱离,平均10.9±5.1个月。
- 色素上皮脱离在12个月内出现于15例(占全部32例的46.8%,占发生色素上皮脱离20例的75.0%)。
- 初诊有浆液性色素上皮脱离而无视网膜下液的52例中15例(28.8%)发生视网膜下液,平均11.2±6.4个月。
- 视网膜下液在12个月内出现于9例(占全部52例的17.3%,占发生视网膜下液15例的66.6%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the incidence and timing of pigment epithelial detachment (PED) and subretinal fluid (SRF) development in type 3 macular neovascularization. METHODS: This retrospective study included 84 patients who were diagnosed with treatment-naïve type 3 macular neovascularization who did not show SRF at diagnosis. All patients were initially treated with three loading injections of ranibizumab or aflibercept. After the initial loading injections, as-needed regimen was performed for retreatment. The development of either PED or SRF was identified. The incidence and timing of PED development in patients without PED at diagnosis and that of SRF development in patients with PED at diagnosis were evaluated. RESULTS: The mean follow-up period was 41.3 ± 20.7 months after diagnosis. Among the 32 patients without serous PED at diagnosis, PED developed in 20 (62.5%) at a mean of 10.9 ± 5.1 months after diagnosis. PED development was noted within 12 months in 15 patients (46.8%; 75.0% among the PED development cases). In 52 patients with serous PED and without SRF at diagnosis, 15 developed SRF (28.8%) at a mean of 11.2 ± 6.4 months after diagnosis. SRF development was noted within 12 months in nine patients (17.3%; 66.6% among the SRF development cases). CONCLUSION: PED and SRF developed in a substantial proportion of patients with type 3 macular neovascularization. The average period of development of these pathologic findings was within 12 months of diagnosis, suggesting the need for active treatment during the early treatment period to improve treatment outcomes.
引用
- Kim JH, Kim JW, Kim CG, et al. INCIDENCE AND TIMING OF PIGMENT EPITHELIAL DETACHMENT AND SUBRETINAL FLUID DEVELOPMENT IN TYPE 3 MACULAR NEOVASCULARIZATION ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION. Retina. 2023. PMID: 36977322. doi:10.1097/IAE.0000000000003797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。